[Skip to Content]
[Skip to Content Landing]
Article
May 1984

Varicella Vaccine Trials in Healthy ChildrenA Summary of Comparative and Follow-up Studies

Author Affiliations

From the Department of Pediatrics, Temple University School of Medicine, Philadelphia (Dr Arbeter); Department of Pediatrics, Albert Einstein Medical Center, Philadelphia (Dr Arbeter); Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia (Drs Starr and Plotkin); Division of Immunizations, Center for Preventive Services, Centers for Disease Control, Atlanta (Dr Preblud); Department of Pediatrics, Mie University School of Medicine, Tsucity, Mie, Japan (Dr Ihara); and Division of Infectious Diseases, Department of Pediatrics, The Children's Hospital of Philadelphia (Drs Starr and Plotkin and Mss Paciorek, Miller, Zelson, and Proctor).

Am J Dis Child. 1984;138(5):434-438. doi:10.1001/archpedi.1984.02140430012004
Abstract

• Beginning in 1979, OKA and KMcC strains of varicella zoster virus (VZV) vaccine were administered to 369 healthy seronegative children in a sequence of ten comparative clinical trials. Postimmunization clinical reactivity was minimal with the OKA vaccines but was unacceptably high (32%) with the KMcC passage-40 vaccine. Ninety-three percent to 100% immunogenicity was noted by fluorescent antibody assay and in vitro lymphocyte proliferation to VZV antigens. Follow-up studies demonstrated persistence of antibody and in vitro lymphocyte proliferation responses and protection or modification of infection nine to 48 months after immunization. Only five episodes of mild varicella occurred in children in whom seroconversion had occurred. These episodes were noted after at least 281 known varicella exposures. Vaccine virus reactivation as zoster had not occurred in any child.

(AJDC 1984;138:434-438)

×